Ultragenyx bags FDA priority review for groundbreaking GSDIa gene therapy

If approved, DTX401 would be the first treatment to address the disease at its root cause

Artemis Medicare to manage 650-bed VIMHANS Hospital in Rs. 520 South Delhi expansion

The project entails a total planned capital expenditure of approximately Rs. 500 - 520 crore

FDA nod to AstraZeneca’s all-oral, fixed-duration therapy for CLL & SLL

The decision follows compelling data from the AMPLIFY Phase III trial, demonstrating that 77% of patients receiving the Calquence-venetoclax combination were progression-free at three years

PharmEasy integrates with Samsung Health to streamline digital healthcare

Samsung Health users can now order medicines, book lab tests and online consultations through PharmEasy, along with 6 months of complimentary PharmEasy Plus membership

BMS reports positive Phase 2 data for Luspatercept in alpha-thalassemia

Both non-transfusion-dependent and transfusion dependent cohorts met their respective primary and secondary endpoints

Lonza scales bioconjugate innovation through enhanced synthesis offering

Expansion at the Oss (NL) site adds capacity and R&D capabilities, supporting the development and manufacturing of ADCs and other novel bioconjugates from First-in-Human to commercialization

Dr Reddy’s enters hormone replacement therapy market with landmark brand acquisition

The acquisition marks the company’s strategic entry into the fast-growing Hormone Replacement Therapy (HRT) segment and significantly strengthens its gynaecology portfolio in India

Asahi Kasei Pharma & Alchemedicine launch first human trials for hard-to-treat diseases drugs

FDA accepts Deciphera’s NDA for tirabrutinib in rare aggressive brain lymphoma

The drug targets relapsed or refractory primary central nervous system lymphoma, a rare and aggressive form of non-Hodgkin lymphoma

Newron Pharmaceuticals bags up to €38 million to fuel Phase III ENIGMA-TRS program

A final tranche of €12 million will follow, contingent on positive pivotal study results, with the share price calculated according to an agreed formula